Cocrystal Pharma, Inc. (COCP): Price and Financial Metrics
COCP Price/Volume Stats
| Current price | $1.63 | 52-week high | $3.26 |
| Prev. close | $1.65 | 52-week low | $1.12 |
| Day low | $1.55 | Volume | 118,000 |
| Day high | $1.81 | Avg. volume | 24,749 |
| 50-day MA | $1.46 | Dividend yield | N/A |
| 200-day MA | $1.80 | Market Cap | 16.58M |
COCP Stock Price Chart Interactive Chart >
Cocrystal Pharma, Inc. (COCP) Company Bio
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
COCP Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
COCP Price Returns
| 1-mo | 3.82% |
| 3-mo | -4.17% |
| 6-mo | -14.21% |
| 1-year | -36.82% |
| 3-year | -67.96% |
| 5-year | -85.39% |
| YTD | -19.31% |
| 2024 | 17.29% |
| 2023 | -11.68% |
| 2022 | -75.00% |
| 2021 | -52.21% |
| 2020 | 174.47% |